Scientific presentations

12

Dec 2023
15:48 E.S.T.

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T-Cell Product Manufactured by Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ (B-ALL) – ASH 2023 – Poster Presentation

Download the PDF file

12

Dec 2023
15:44 E.S.T.

Preliminary Results of NatHaLi-01: A First-In-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL) – ASH 2023 – Poster Presentation

Download the PDF file

5

Nov 2023
20:16 E.S.T.

TGFBR2 KO combined with activation-induced IL12 secretion synergize to optimize potency and safety of MUC1-CAR T-cells in preclinical targeting of triple-negative breast cancer – SITC 2023 – Poster Presentation

Download the PDF file

27

Oct 2023
08:41 E.S.T.

Comprehensive Analysis of the Editing Window of TALE Base Editors – ESGCT 2023 – Poster Presentation

Download the PDF file

27

Oct 2023
08:38 E.S.T.

Intronic editing enables lineage-specific expression of therapeutics relevant for HSPC gene therapy – ESGCT 2023 – Poster presentation

Download the PDF file

27

Oct 2023
08:34 E.S.T.

Non-Viral DNA Delivery Coupled To TALEN Gene Editing Efficiently Correct The Sickle Cell Mutation In Long-Term HSCS – ESGCT 2023 – Poster Presentation

Download the PDF file

22

Sep 2023
13:06 E.S.T.

TALEN®-Edited Inducible Dual Car T-Cells Aimed at Safe and Effective Targeting Of Solid Tumors – CICON 2023 – Poster Presentation

Download the PDF file

8

Jun 2023
08:21 E.S.T.

Updated Results of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR T-cell Product, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) – EHA 2023 – Poster Presentation

Download the PDF file

5

Jun 2023
10:53 E.S.T.

UCART20x22: allogeneic dual CAR T-cells for the treatment of B-cell malignancies – ISCT 2023 – Oral Presentation

Download the PDF file

5

Jun 2023
07:29 E.S.T.

Comprehensive Analysis of the Editing Window of TALE Base Editors ISCT 2023 – Poster Presentation

Download the PDF file

Scientific presentations

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T-Cell Product Manufactured by Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ (B-ALL) – ASH 2023 – Poster Presentation

Preliminary Results of NatHaLi-01: A First-In-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL) – ASH 2023 – Poster Presentation

TGFBR2 KO combined with activation-induced IL12 secretion synergize to optimize potency and safety of MUC1-CAR T-cells in preclinical targeting of triple-negative breast cancer – SITC 2023 – Poster Presentation

Comprehensive Analysis of the Editing Window of TALE Base Editors – ESGCT 2023 – Poster Presentation

Intronic editing enables lineage-specific expression of therapeutics relevant for HSPC gene therapy – ESGCT 2023 – Poster presentation

Non-Viral DNA Delivery Coupled To TALEN Gene Editing Efficiently Correct The Sickle Cell Mutation In Long-Term HSCS – ESGCT 2023 – Poster Presentation

TALEN®-Edited Inducible Dual Car T-Cells Aimed at Safe and Effective Targeting Of Solid Tumors – CICON 2023 – Poster Presentation

Updated Results of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR T-cell Product, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) – EHA 2023 – Poster Presentation

UCART20x22: allogeneic dual CAR T-cells for the treatment of B-cell malignancies – ISCT 2023 – Oral Presentation

Comprehensive Analysis of the Editing Window of TALE Base Editors ISCT 2023 – Poster Presentation

Scientific publications